Objective To understand the latest research developments of the formation mechanism of psammoma body in human tumors and related issues. Methods Related domestic and foreign literatures were widely referred, analyzed, and reviewed. Results Psammoma body is unique pathological calcification in some tumors, which is arranged in concentric, laminar circles microscopically. Psammoma body is commonly seen in thyroid papillary carcinoma, meningiomas, ovarian serous papillary carcinoma, and so on. Conclusions Although arranged in concentric, laminar circles microscopically in tumor, the formation process of psammoma body is not entirely the same in different tumors. A comprehensive and objective understanding of psammoma body would be useful in cancer diagnosis and treatment.
Objective To evaluate the role of systematic lymphadenectomy (SL) vs. unsystematic lymphadenectomy (USL) for improving overall survival (OS) in epithelial ovarian cancer (EOC). Methods The databases such as PubMed, EMbase, The Cochrane Library, Evidence-Based Medicine Reviews (EBMR), CBM, CNKI and VIP were searched between January 1, 1995 and December 31, 2010, the randomized controlled trials (RCTs) and observational studies on SL vs. USL in treating EOC were included. Based on Cochrane handbook, the data were extracted, the methodological quality was assessed, and then meta-analyses were conducted by using RevMan 5.0 software. Results The total 13 studies involving 22 796 patients were included, including 5 420 patients in the SL group, and the other 17 376 patients in the USL group. Two of the 13 studies were RCTs, and the other 11 were observational studies (including 2 studies retrieved from SEER data). The analyses on 2 RCTs showed that compared with USL, a) SL could not improve 5-PFS (OR=0.70, 95%CI 0.40 to 1.22, P=0.21) in early-stage EOC (FIGO I to II), but it did improve 5-PFS (OR=0.62, 95%CI 0.40 to 0.96, P=0.03) in advanced-stage EOC (FIGO III to IV); b) SL could not improve 5-OS in both early-stage EOC (OR=0.84; 95%CI 0.44 to1.58, P=0.58) and advanced-stage EOC (OR=0.93, 95%CI 0.64 to 1.37, P=0.73); and c) SL could not improve 5-OS in both early-stage (OR=0.84, 95%CI 0.44 to 1.58, P=0.58) and advanced-stage (OR=0.93, 95%CI 0.64 to 1.37, P=0.73) of EOC patients who had optimal tumor dubulking surgery. The analyses on observational studies showed that compared with USL, a) SL could not improve 5-PFS in both early-stage EOC (OR=0.38, 95%CI 0.08 to 1.74, P=0.21) and advanced-stage (OR=2.88, 95%CI 0.95 to 8.72, P=0.06) EOC; b) Whether SEER impacts were excluded or not, SL did improve 5-OS in both early-stage EOC (OR=0.54, 95%CI 0.46 to 0.63, Plt;0.000 01) and advanced-stage (OR=0.47, 95%CI 0.43 to 0.52, Plt;0.000 01) EOC; and c) For EOC patients who had optimal tumor dubulking surgery, SL could not improve 5-OS in early-stage (OR=0.32, 95% CI 0.02 to 6.19, P=0.45), but it did improve 5-OS in advanced-stage (OR=0.53, 95%CI 0.32 to 0.88, P=0.01). Conclusion These findings suggest that maybe SL can improve 5-PFS and 5-OS in EOC. However, the efficacy of SL on 5-PFS and 5-OS is still undetermined, so more relevant studies are required for further investigating the role of SL in EOC.
Objective To use a meta-analysis method to establish quantitatively the association between the HER-2/neu gene amplification/enhanced protein expression status and the 5-year post-operative survival rate or median survival time in women with epithelial ovarian carcinoma. Methods We searched and screened Chinese and English literature published since 1989 to collect all retrospective cohort studies on the prognostic significance of HER-2/neu status in this population. The survival data were analyzed using Ludwig’s centered signed rank and the DerSimonian-Laird method. Results In total, 25 studies involving 3 251 patients were included. HER-2/neu was positive in 27.1% (95%CI 0 to 54.8%) of patients, which was not related to the pathological stage, type or grade of epithelial ovarian carcinoma. In HER-2/neu positive cases, the median survival time was shortened by 0.65 years, and the 5-year survival rate was lowered. The hazard ratio (HR) for mortality was 1.22 (95%C 1.09 to 1.36). By subgroup analysis, HER-2/neu protein expression was found to be most significant in prognostic assessment. Patients with a b positive value of HER-2/neu had an increased HR for the 5-year survival; and platinum-based chemotherapy was demonstrated to be less effective in HER-2/neu positive ovarian carcinoma. Conclusion In gynecological oncology, it is reasonable to measure HER-2/neu as a routine pathological marker to predict a patient’s prognosis and to determine the most appropriate adjuvant chemotherapy regimen.
Objective To explore the differential expression of circular RNAs (circRNAs) in polycystic ovary syndrome (PCOS) by bioinformatics, and predict the microRNAs (miRNAs) associated with them. Methods The expression profile of cumulus cells gene chip in PCOS was searched in the Gene Expression Omnibus database, and differential circRNAs were screened by GEO2R tool of the database. The Gene Ontology and Kyoto Encyclopedia of Genes and Genomes signaling pathways of different circRNA genes were analyzed using the DAVID 6.8 database. Circular RNA interactome was used to predict the potential regulated miRNAs. Cytoscape software was used to establish circRNA-miRNA network map. The potential regulatory miRNAs were predicted by the 10 circRNAs with the most significant differences in up-regulation and down-regulation. Results A total of 247 circRNAs were obtained in PCOS, and 277 miRNAs binding to up-regulated circRNA genes and 125 miRNAs binding to down-regulated circRNA genes were predicted. The top 10 miRNAs that could bind to multiple differential circRNAs were hsa-miR-557, hsa-miR-507, hsa-miR-224, hsa-miR-136, hsa-miR-127-5p, hsa-miR-579, hsa-miR-502-5p, hsa-miR-186, hsa-miR-1253, and hsa-miR-432. Conclusion The differential expression analysis of circRNAs is helpful to understand the main role of circRNAs in PCOS, and the prediction of potential regulated miRNAs can help to understand the pathogenesis of the disease.
Objective To systematically review the diagnostic value of 18F-FDG PET/CT in recurrent epithelial ovarian cancer after treatment. Methods The PubMed, EMbase, Cochrane Library, Web of Science, CNKI, WanFang Data, VIP, and CBM databases were electronically searched to collect diagnostic tests of 18F-FDG PET/CT for epithelial ovarian cancer from inception to February 2023. Two reviewers independently screened the literature, extracted data, and assessed the risk of bias of the included studies. Meta-analysis was then performed using Meta-Disc 1.4 and Stata 15.0 software. Results A total of 15 studies involving 792 patients were included in this study. The results of meta-analysis showed that the sensitivity, specificity, and area under the curve of 18F-FDG PET/CT in the diagnosis of recurrent epithelial ovarian cancer were 0.88 (95%CI 0.85 to 0.90), 0.80 (95%CI 0.75 to 0.85) and 0.91, respectively. The results of the subgroup analysis showed that the sensitivity of the prospective studies was the same as that of the retrospective studies, but the specificity of the prospective studies was higher than that of the retrospective studies. The diagnostic sensitivity and specificity of 18F-FDG PET/CT in recurrent epithelial ovarian cancer were higher in Asian studies than in European/North American studies. Conclusion 18F-FDG PET/CT has high diagnostic value in recurrent epithelial ovarian cancer. Due to the limited quantity and quality of the included studies, more high-quality studies are needed to verify the above conclusion.
ObjectiveTo determine if the anti-apoptosis agent can improve the protective effect of human ovarian tissue with novel vitrification method.
MethodsHuman ovarian cortical tissues were collected from ten patients treated between October 2012 and August 2013. The samples obtained from each patient were divided into two groups:control (the novel immersed vitrification) and experimental group (the novel immersed vitrification supplemented with vitamin C). The preservation effects in the two groups were compared by ultrastructure using electronic microscopy, and apoptosis was assessed by terminal deoxynucleotidyl transferase-medicated dUTP nick-end labeling (TUNEL) staining.
ResultsThe proportion of normal ultrastructure of oocytes and granulosa cells in the experimental group was higher than that in the control group (P<0.05). The proportion of TUNEL-positive primordial follicles in the experimental group was 21.6% (49/227) and the proportion of TUNEL-positive primordial follicles in the control group was 38.6% (91/236), with a significant difference between the two groups (P<0.001). The proportion of TUNEL-positive stromal cells in the experimental group was (21.33±3.41)% and the proportion of TUNEL-positive stromal cells in the control group was (33.46±3.09)%, also with a significant difference between the two groups (P<0.001).
ConclusionAnti-apoptosis agents can improve the preservation of primordial follicles and stromal cells by inhibiting of apoptosis. It may be a method worthy of trying in order to improve the protective effect of human ovarian tissue vitrification.
【摘要】 目的 探討超聲引導介入治療卵巢囊腫的經驗和方法。 方法 回顧性分析2004年8月－2009年12月超聲引導下治療卵巢囊腫180例，抽出囊腫內液后注入無水乙醇，觀察臨床療效。 結果 179例（99.4%）治療成功，無嚴重并發癥發生，術后2年隨訪，3例（1.7%）復發。 結論 超聲引導介入治療卵巢囊腫療效滿意。【Abstract】 Objective To investigate the experiences and methods of interventional ultrasound treatment of ovarian cysts. Methods We retrospectively analyze the clinical data of 180 patients with ovarian cysts undergoing ultrasound-guided treatment. The clinical effect was observed after alcohol sclerosis therapy. Results A total of 179 patients (99.4%) were successfully treated by the ultrasound-guided aspiration without severe significant complications. Three patients (1.7%) recurred during the 24-month follow-up. Conclusion The clinical effect of ultrasound-guided aspiration and alcohol sclerosis was satisfactory.
